Is InMed Pharmaceuticals Stock a Good Investment?
InMed Pharmaceuticals Investment Advice | INM |
- Examine InMed Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research InMed Pharmaceuticals' leadership team and their track record. Good management can help InMed Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact InMed Pharmaceuticals' business and its evolving consumer preferences.
- Compare InMed Pharmaceuticals' performance and market position to its competitors. Analyze how InMed Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if InMed Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about InMed Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in InMed Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if InMed Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine InMed Pharmaceuticals Stock
Researching InMed Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. InMed Pharmaceuticals recorded earning per share (EPS) of 230.4. The entity last dividend was issued on the 6th of July 2020. The firm had 1:20 split on the 14th of November 2024.
To determine if InMed Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding InMed Pharmaceuticals' research are outlined below:
| InMed Pharmaceuticals had very high historical volatility over the last 90 days | |
| InMed Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.6 M. Reported Net Loss for the year was (7.68 M) with profit before taxes, overhead, and interest of 1.4 M. | |
| InMed Pharmaceuticals has about 9.35 M in cash with (6.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| InMed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System |
InMed Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in InMed Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to InMed Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 16th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact InMed Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises InMed Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.22 | -0.1017 | 0.1183 | 53 | ||
2020-09-08 | 2020-06-30 | -0.66 | -0.44 | 0.22 | 33 | ||
2019-05-15 | 2019-03-31 | -0.33 | -0.66 | -0.33 | 100 | ||
2023-09-29 | 2023-06-30 | -4.25 | -3.25 | 1.0 | 23 | ||
2021-09-24 | 2021-06-30 | -8.5 | -10.25 | -1.75 | 20 | ||
2022-02-13 | 2021-12-31 | -5.87 | -7.75 | -1.88 | 32 | ||
2021-11-10 | 2021-09-30 | -8.75 | -6.25 | 2.5 | 28 | ||
2021-02-11 | 2020-12-31 | -6 | -9.25 | -3.25 | 54 |
Know InMed Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as InMed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading InMed Pharmaceuticals backward and forwards among themselves. InMed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase InMed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Global Retirement Partners, Llc. | 2024-09-30 | 6.0 | The Toronto-dominion Bank | 2024-06-30 | 2.0 | Bfsg, Llc | 2024-06-30 | 0.0 | Td Waterhouse Canada Inc | 2024-09-30 | 0.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Advisornet Financial, Inc | 2024-06-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Advisorshares Investments, Llc | 2024-09-30 | 733.3 K | Sabby Management Llc | 2024-06-30 | 307.2 K |
InMed Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a total capitalization of 3.78 M.Market Cap |
|
InMed Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (4.61) | |
| Return On Capital Employed | 5.93 | 6.23 | |
| Return On Assets | (0.65) | (2.78) | |
| Return On Equity | (0.83) | 6.45 |
Determining InMed Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if InMed Pharmaceuticals is a good buy. For example, gross profit margin measures InMed Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of InMed Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate InMed Pharmaceuticals' management efficiency
InMed Pharmaceuticals has Return on Asset of (0.3922) % which means that on every $100 spent on assets, it lost $0.3922. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7209) %, meaning that it generated no profit with money invested by stockholders. InMed Pharmaceuticals' management efficiency ratios could be used to measure how well InMed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, InMed Pharmaceuticals' Return On Capital Employed is very stable compared to the past year. As of the 15th of December 2024, Return On Equity is likely to grow to 6.45, while Return On Tangible Assets are likely to drop (4.61). At this time, InMed Pharmaceuticals' Tangible Asset Value is very stable compared to the past year. As of the 15th of December 2024, Intangibles To Total Assets is likely to grow to 0.40, while Net Tangible Assets are likely to drop about 9.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.21 | (17.32) | |
| Net Current Asset Value | -39.7 K | -41.7 K | |
| Tangible Asset Value | 1.5 M | 2 M | |
| Tangible Book Value Per Share | 0.98 | (33.20) | |
| Enterprise Value Over EBITDA | (4.61) | (2.02) | |
| Price Book Value Ratio | 4.14 | (7.61) | |
| Enterprise Value Multiple | (4.61) | (2.02) | |
| Price Fair Value | 4.14 | (7.61) | |
| Enterprise Value | 32.5 M | 1.9 M |
Leadership effectiveness at InMed Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.711 |
Basic technical analysis of InMed Stock
As of the 15th of December 2024, InMed Pharmaceuticals retains the risk adjusted performance of 0.0226, and Market Risk Adjusted Performance of (0.24). InMed Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out InMed Pharmaceuticals coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if InMed Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 5.26 per share. Given that InMed Pharmaceuticals has jensen alpha of 0.1627, we strongly advise you to confirm InMed Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.InMed Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific InMed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on InMed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases InMed Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
InMed Pharmaceuticals' Outstanding Corporate Bonds
InMed Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. InMed Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most InMed bonds can be classified according to their maturity, which is the date when InMed Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand InMed Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing InMed Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0226 | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 4.77 | |||
| Semi Deviation | 6.38 | |||
| Downside Deviation | 6.82 | |||
| Coefficient Of Variation | 5295.51 | |||
| Standard Deviation | 6.87 | |||
| Variance | 47.19 | |||
| Information Ratio | 0.0043 | |||
| Jensen Alpha | 0.1627 | |||
| Total Risk Alpha | (0.73) | |||
| Sortino Ratio | 0.0043 | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 39.14 | |||
| Value At Risk | (9.22) | |||
| Potential Upside | 10.0 | |||
| Downside Variance | 46.5 | |||
| Semi Variance | 40.73 | |||
| Expected Short fall | (5.05) | |||
| Skewness | 0.4134 | |||
| Kurtosis | 1.92 |
| Risk Adjusted Performance | 0.0226 | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 4.77 | |||
| Semi Deviation | 6.38 | |||
| Downside Deviation | 6.82 | |||
| Coefficient Of Variation | 5295.51 | |||
| Standard Deviation | 6.87 | |||
| Variance | 47.19 | |||
| Information Ratio | 0.0043 | |||
| Jensen Alpha | 0.1627 | |||
| Total Risk Alpha | (0.73) | |||
| Sortino Ratio | 0.0043 | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 39.14 | |||
| Value At Risk | (9.22) | |||
| Potential Upside | 10.0 | |||
| Downside Variance | 46.5 | |||
| Semi Variance | 40.73 | |||
| Expected Short fall | (5.05) | |||
| Skewness | 0.4134 | |||
| Kurtosis | 1.92 |
Consider InMed Pharmaceuticals' intraday indicators
InMed Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of InMed Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
InMed Pharmaceuticals Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 28th of October 2024 Other Reports | ViewVerify | |
| 17th of October 2024 Other Reports | ViewVerify |
InMed Stock media impact
Far too much social signal, news, headlines, and media speculation about InMed Pharmaceuticals that are available to investors today. That information is available publicly through InMed media outlets and privately through word of mouth or via InMed internal channels. However, regardless of the origin, that massive amount of InMed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of InMed Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of InMed Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to InMed Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive InMed Pharmaceuticals alpha.
InMed Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards InMed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
InMed Pharmaceuticals Corporate Management
| Sazzad MSc | CoFounder | Profile | |
| Ado Muhammad | Consultant Affairs | Profile | |
| Colin Clancy | Director Relations | Profile | |
| Eric Hsu | Senior Development | Profile | |
| Jerry Griffin | Vice Marketing | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between InMed Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.